scispace - formally typeset
J

Jessica Saunders

Researcher at Monash University

Publications -  13
Citations -  492

Jessica Saunders is an academic researcher from Monash University. The author has contributed to research in topics: Fexinidazole & In vivo. The author has an hindex of 8, co-authored 12 publications receiving 375 citations. Previous affiliations of Jessica Saunders include Monash University, Parkville campus.

Papers
More filters
Journal ArticleDOI

Transformation of Poorly Water-Soluble Drugs into Lipophilic Ionic Liquids Enhances Oral Drug Exposure from Lipid Based Formulations

TL;DR: The data suggest that the formation of lipophilic ionic liquids provides a means of increasing dissolved-drug loading in lipid based formulations and thereby promoting the exposure of poorly water-soluble drugs after oral administration.
Journal ArticleDOI

An in vitro toolbox to accelerate anti-malarial drug discovery and development

TL;DR: This is the first data set to describe in vitro properties for 45 legacy and development anti-malarial drugs and will be a valuable tool for malaria researchers aiming to develop PBPK models for the prediction of human PK properties and/or drug–drug interactions.
Journal ArticleDOI

Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage.

TL;DR: A systematic study of nitroheterocyclic drug efficacy using highly sensitive bioluminescence imaging of murine infections finds both drugs are more effective at curing chronic infections, judged by treatment duration and therapeutic dose.
Journal ArticleDOI

Antitrypanosomal Activity of Fexinidazole Metabolites, Potential New Drug Candidates for Chagas Disease

TL;DR: Pharmacokinetic data suggested that biological efficacy most likely resides with the sulfone metabolite (or subsequent reactive metabolites formed following reduction of the nitro group) following administration of either the sulfoxide or the sulf one and that prolonged plasma exposure over the 24-h dosing window is required to achieve high cure rates.